Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-03-14
Schrödinger, Inc.
Schrödinger sells computational chemistry and discovery informatics software and also uses its platform to generate collaboration, milestone, and royalty-bearing drug discovery economics.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Hosted reset with real platform upside
The upside case is a quality-improvement story disguised as a reset. If hosted delivery, workflow trust, and capital-light discovery economics all prove out, the shares can rerate meaningfully without requiring an extreme biotech outcome.

Analysis

Thesis
Over the next five years, Schrödinger can turn a noisy hosted-transition period into a better business: a stickier discovery operating layer with improving software quality, selective trust-based monetization, and capital-light royalty upside.
Last Economy Alignment
Cheaper AI should expand computational discovery demand, and Schrödinger owns a real workflow plus physics layer inside that stack. But it does not own the core compute bottleneck, and some value can leak to internal pharma stacks or lower-cost agents.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
5.5x (from 5 most recent analyses)
Reasoning
The upside is a quality-improvement rerating, not a moonshot. If investors begin to underwrite Schrödinger as a hosted, retention-led discovery workflow company with capital-light downstream economics, the stock can move from hybrid-tools skepticism toward a better software multiple. I still cap the rerating because therapeutics value is externally gated and pharma buyers can internalize pieces of the stack.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main failure mode is category confusion: the hosted transition could obscure real demand, the workflow layer may not deepen enough to prevent substitution, and therapeutic upside now depends heavily on external partners rather than internal spend. If ACV, retention, and partner-funded development do not all hold together, the stock can stay trapped as a discounted hybrid of tools and biotech.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.47
It controls a real workflow layer for molecular discovery, so more AI can send more work through its system instead of replacing it outright. The threat is that pharma builds its own stack or cheap agents turn the science engine into a feature unless the company owns the trusted record of work.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$22.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case